CCCC stock · CUBE stock

CCCC vs CUBE

C4 Therapeutics Inc (CCCC) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.

C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.

CubeSmart (CUBE) is a reit - industrial company listed on US.

Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.

Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.

CCCC currently screens at market cap $425.7M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.

Not investment advice. Open the CCCC and CUBE stock pages for the full models.

Not investment advice.

Popular Stock Comparisons